<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36917814</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1947-5446</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Annual review of chemical and biomolecular engineering</Title><ISOAbbreviation>Annu Rev Chem Biomol Eng</ISOAbbreviation></Journal><ArticleTitle>Outsmarting Pathogens with Antibody Engineering.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>241</EndPage><MedlinePgn>217-241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1146/annurev-chembioeng-101121-084508</ELocationID><Abstract><AbstractText>There is growing interest in identifying antibodies that protect against infectious diseases, especially for high-risk individuals and pathogens for which no vaccine is yet available. However, pathogens that manifest as opportunistic or latent infections express complex arrays of virulence-associated proteins and are adept at avoiding immune responses. Some pathogens have developed strategies to selectively destroy antibodies, whereas others create decoy epitopes that trick the host immune system into generating antibodies that are at best nonprotective and at worst enhance pathogenesis. Antibody engineering strategies can thwart these efforts by accessing conserved neutralizing epitopes, generating Fc domains that resist capture or degradation and even accessing pathogens hidden inside cells. Design of pathogen-resistant antibodies can enhance protection and guide development of vaccine immunogens against these complex pathogens. Here, we discuss general strategies for design of antibodies resistant to specific pathogen defense mechanisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qerqez</LastName><ForeName>Ahlam N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, The University of Texas, Austin, Texas, USA; email: maynard@che.utexas.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Rui P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Molecular Biosciences, The University of Texas, Austin, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maynard</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering, The University of Texas, Austin, Texas, USA; email: maynard@che.utexas.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI155453</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Annu Rev Chem Biomol Eng</MedlineTA><NlmUniqueID>101574034</NlmUniqueID><ISSNLinking>1947-5438</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000941">Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000941" MajorTopicYN="N">Antigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fc engineering</Keyword><Keyword MajorTopicYN="N">antibody&#x2013;drug conjugate</Keyword><Keyword MajorTopicYN="N">bispecific antibody</Keyword><Keyword MajorTopicYN="N">immune evasion</Keyword><Keyword MajorTopicYN="N">passive immunization</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>17</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36917814</ArticleId><ArticleId IdType="mid">NIHMS1892641</ArticleId><ArticleId IdType="pmc">PMC10330301</ArticleId><ArticleId IdType="doi">10.1146/annurev-chembioeng-101121-084508</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, et al. 2019. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell 179: 1636&#x2013;46 e15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158953</ArticleId><ArticleId IdType="pubmed">31787378</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrioli A, Oxenius A. 2021. Single B cell technologies for monoclonal antibody discovery. Trends Immunol 42: 1143&#x2013;58</Citation><ArticleIdList><ArticleId IdType="pubmed">34743921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, et al. 2015. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7: 309ra162</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672383</ArticleId><ArticleId IdType="pubmed">26468324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, et al. 2017. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 9: eaaj1928</Citation><ArticleIdList><ArticleId IdType="pubmed">28469033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron HC, Tripp RA. 2022. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert Opin Investig Drugs 31: 23&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pubmed">34937485</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang J, Jian F, Xiao T, Song W, et al. 2022. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602: 657&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr., et al. 2022. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Jette CA, Cohen AA, Gnanapragasam PNP, Muecksch F, Lee YE, et al. 2021. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Rep 36: 109760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423902</ArticleId><ArticleId IdType="pubmed">34534459</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Czudnochowski N, Liu Z, Zatta F, Park YJ, et al. 2021. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597: 97&#x2013;102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282883</ArticleId><ArticleId IdType="pubmed">34261126</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y, Huang W, Liu H, Sang Z, Nambulli S, et al. 2022. Superimmunity by pan-sarbecovirus nanobodies. Cell Rep 39: 111004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174178</ArticleId><ArticleId IdType="pubmed">35738279</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, et al. 2020. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370: 1479&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857400</ArticleId><ArticleId IdType="pubmed">33154108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S, Nachbagauer R, Balmaseda A, Stadlbauer D, Ojeda S, et al. 2019. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nature Medicine 25: 962&#x2013;67</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608747</ArticleId><ArticleId IdType="pubmed">31160818</ArticleId></ArticleIdList></Reference><Reference><Citation>Doud MB, Lee JM, Bloom JD. 2018. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nature Communications 9: 1386</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5895760</ArticleId><ArticleId IdType="pubmed">29643370</ArticleId></ArticleIdList></Reference><Reference><Citation>DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20: 143&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966466</ArticleId><ArticleId IdType="pubmed">24412922</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthmiller JJ, Han J, Utset HA, Li L, Lan LY, et al. 2022. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature 602: 314&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828479</ArticleId><ArticleId IdType="pubmed">34942633</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Nguyen AW, Hsieh C-L, Silva R, Olaluwoye OS, et al. 2021. Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses. bioRxiv</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10030117</ArticleId><ArticleId IdType="pubmed">36942851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Kwon HJ, Cachau R, Chen CZ, Butay KJ, et al. 2021. Camel nanobodies broadly neutralize SARS-CoV-2 variants. bioRxiv : the preprint server for biology: 2021.10.27.465996</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170159</ArticleId><ArticleId IdType="pubmed">35476528</ArticleId></ArticleIdList></Reference><Reference><Citation>Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, et al. 2016. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci U S A 113: 2714&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4791009</ArticleId><ArticleId IdType="pubmed">26888286</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin SW, Pawloski L, Williams M, Weening K, DeBolt C, et al. 2015. Pertactin-Negative Bordetella pertussis Strains: Evidence for a Possible Selective Advantage. Clin Infect Dis 60: 223&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">25301209</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Gingerich AD, Royer F, Paschall AV, Pena-Briseno A, et al. 2021. Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection. Infect Immun 89</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091081</ArticleId><ArticleId IdType="pubmed">33649050</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingerich AD, Royer F, McCormick AL, Scasny A, Vidal JE, Mousa JJ. 2022. Synergistic Protection against Secondary Pneumococcal Infection by Human Monoclonal Antibodies Targeting Distinct Epitopes. J Immunol</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9898123</ArticleId><ArticleId IdType="pubmed">36351696</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Di L, Akther S, Zeglis BM, Qiu W. 2022. Evolution of the vls Antigenic Variability Locus of the Lyme Disease Pathogen and Development of Recombinant Monoclonal Antibodies Targeting Conserved VlsE Epitopes. Microbiol Spectr 10: e0174322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9604149</ArticleId><ArticleId IdType="pubmed">36150043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Werner AP, Leist SR, Stevens LJ, Falconer E, et al. 2021. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Rep 37: 109929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8519809</ArticleId><ArticleId IdType="pubmed">34710354</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader JW, McLean GR. 2007. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies. Immunol Lett 112: 58&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">17714794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Excler JL, Michael NL. 2015. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 66: 423&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">25341006</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, et al. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509: 55&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4395007</ArticleId><ArticleId IdType="pubmed">24590074</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, et al. 2019. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLOS Pathogens 15: e1008064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936867</ArticleId><ArticleId IdType="pubmed">31841557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, et al. 2019. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Rep 28: 877&#x2013;95.e6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666430</ArticleId><ArticleId IdType="pubmed">31340151</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M, Wu NC, Zhu X, Lee CD, So RTY, et al. 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164391</ArticleId><ArticleId IdType="pubmed">32245784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. 2014. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158: 1243&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4167398</ArticleId><ArticleId IdType="pubmed">25215485</ArticleId></ArticleIdList></Reference><Reference><Citation>Veillette M, Coutu M, Richard J, Batraville L-A, Dagher O, et al. 2015. The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. Journal of Virology 89: 545&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301108</ArticleId><ArticleId IdType="pubmed">25339767</ArticleId></ArticleIdList></Reference><Reference><Citation>Madani N, Princiotto AM, Mach L, Ding S, Prevost J, et al. 2018. A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nature Communications 9: 2363</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6006336</ArticleId><ArticleId IdType="pubmed">29915222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong PD, Wilson IA. 2009. HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796958</ArticleId><ArticleId IdType="pubmed">19448659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D, Fenwick C, Caillat C, Silacci C, Guseva S, et al. 2019. Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell Host Microbe 26: 623&#x2013;37.e8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6854463</ArticleId><ArticleId IdType="pubmed">31653484</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, et al. 2019. Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity 50: 677&#x2013;91.e13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6555550</ArticleId><ArticleId IdType="pubmed">30876875</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulsen BE, Yang R, Clatworthy AE, White T, Osmulski SJ, et al. 2019. Defining the core essential genome of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 116: 10072&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6525520</ArticleId><ArticleId IdType="pubmed">31036669</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher MW, Devlin HB, Gnabasik FJ. 1969. New immunotype schema for Pseudomonas aeruginosa based on protective antigens. J Bacteriol 98: 835&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC284896</ArticleId><ArticleId IdType="pubmed">4977486</ArticleId></ArticleIdList></Reference><Reference><Citation>Knirel YA. 1990. Polysaccharide antigens of Pseudomonas aeruginosa. Crit Rev Microbiol 17: 273&#x2013;304</Citation><ArticleIdList><ArticleId IdType="pubmed">1698385</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, et al. 2010. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother 54: 2338&#x2013;44</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876355</ArticleId><ArticleId IdType="pubmed">20308370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cywes-Bentley C, Skurnik D, Zaidi T, Roux D, Deoliveira RB, et al. 2013. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci U S A 110: E2209&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683766</ArticleId><ArticleId IdType="pubmed">23716675</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques P, Dello Iacono L, Gimeno A, Biolchi A, Romano MR, et al. 2020. Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide. Proc Natl Acad Sci U S A 117: 29795&#x2013;802</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703565</ArticleId><ArticleId IdType="pubmed">33158970</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman C, Walduck AK, Yuriev E, Richards JS, Cywes-Bentley C, et al. 2018. Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetylglucosamine. J Biol Chem 293: 5079&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5892565</ArticleId><ArticleId IdType="pubmed">29449370</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong R, Kajihara K, Chen M, Hotzel I, Mariathasan S, et al. 2018. Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid. MAbs 10: 979&#x2013;91</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204806</ArticleId><ArticleId IdType="pubmed">30102105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdilek A, Huang J, Babb R, Paschall AV, Middleton DR, et al. 2021. A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies. mBio 12: e0080021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262990</ArticleId><ArticleId IdType="pubmed">34061603</ArticleId></ArticleIdList></Reference><Reference><Citation>Storek KM, Auerbach MR, Shi H, Garcia NK, Sun D, et al. 2018. Monoclonal antibody targeting the beta-barrel assembly machine of Escherichia coli is bactericidal. Proc Natl Acad Sci U S A 115: 3692&#x2013;97</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889671</ArticleId><ArticleId IdType="pubmed">29555747</ArticleId></ArticleIdList></Reference><Reference><Citation>Storek KM, Chan J, Vij R, Chiang N, Lin Z, et al. 2019. Massive antibody discovery used to probe structure-function relationships of the essential outer membrane protein LptD. Elife 8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592684</ArticleId><ArticleId IdType="pubmed">31237236</ArticleId></ArticleIdList></Reference><Reference><Citation>DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, et al. 2012. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 209: 1273&#x2013;87</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405507</ArticleId><ArticleId IdType="pubmed">22734046</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, et al. 2019. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect 25: 629 e1&#x2013;29 e6</Citation><ArticleIdList><ArticleId IdType="pubmed">30107283</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhivker GM, Agajanian S, Oztas DY, Gupta G. 2021. Atomistic Simulations and In Silico Mutational Profiling of Protein Stability and Binding in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Molecular Determinants of Mutational Escape Mechanisms. ACS Omega 6: 26354&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515575</ArticleId><ArticleId IdType="pubmed">34660995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashor L, Gagne RB, Bosco-Lauth AM, Bowen RA, Stenglein M, VandeWoude S. 2021. SARS-CoV-2 evolution in animals suggests mechanisms for rapid variant selection. Proceedings of the National Academy of Sciences 118: e2105253118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8612357</ArticleId><ArticleId IdType="pubmed">34716263</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijers M, Vanshylla K, Gruell H, Klein F, L&#xe4;ssig M. 2021. Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody. Proceedings of the National Academy of Sciences 118: e2104651118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8325275</ArticleId><ArticleId IdType="pubmed">34301904</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, et al. 2021. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371: 850&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963219</ArticleId><ArticleId IdType="pubmed">33495308</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Huddleston J, Doud MB, Hooper KA, Wu NC, et al. 2018. Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants. Proceedings of the National Academy of Sciences 115: E8276&#x2013;E85</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126756</ArticleId><ArticleId IdType="pubmed">30104379</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson A, Li H, Ma B, Weiss R, Bendayan D, et al. 2021. Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis. Nat Commun 12: 602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7840946</ArticleId><ArticleId IdType="pubmed">33504803</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzales SJ, Clarke KN, Batugedara G, Garza R, Braddom AE, et al. 2022. A Molecular Analysis of Memory B Cell and Antibody Responses Against Plasmodium falciparum Merozoite Surface Protein 1 in Children and Adults From Uganda. Front Immunol 13: 809264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9201334</ArticleId><ArticleId IdType="pubmed">35720313</ArticleId></ArticleIdList></Reference><Reference><Citation>Delidakis G, Kim JE, George K, Georgiou G. 2022. Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations. Annu Rev Biomed Eng 24: 249&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648538</ArticleId><ArticleId IdType="pubmed">35363537</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla R, Ramasamy V, Shanmugam RK, Ahuja R, Khanna N. 2020. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Frontiers in Cellular and Infection Microbiology 10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7642463</ArticleId><ArticleId IdType="pubmed">33194810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, et al. 2017. IgG antibodies to dengue enhanced for Fc&#x3b3;RIIIA binding determine disease severity. Science 355: 395&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557095</ArticleId><ArticleId IdType="pubmed">28126818</ArticleId></ArticleIdList></Reference><Reference><Citation>Parke JA, Avis PJ. 1964. The Effect of Digestion with Papain and Pepsin Upon the Antitoxic Activity of Rabbit Antibody. Immunology 7: 248&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1423371</ArticleId><ArticleId IdType="pubmed">14169109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing AJ, Thorpe SJ, Miller K, Mangan M, Varley PG, et al. 2002. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 81: 41&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">11841844</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin M, Olsen A. 2001. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 69: 7187&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC100124</ArticleId><ArticleId IdType="pubmed">11598100</ArticleId></ArticleIdList></Reference><Reference><Citation>von Pawel-Rammingen U, Johansson BP, Bjorck L. 2002. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 21: 1607&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125946</ArticleId><ArticleId IdType="pubmed">11927545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan MH, Petrone D, Nemeth JF, Barnathan E, Bjorck L, Jordan RE. 2008. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 45: 1837&#x2013;46</Citation><ArticleIdList><ArticleId IdType="pubmed">18157932</ArticleId></ArticleIdList></Reference><Reference><Citation>Fick RB Jr., Baltimore RS, Squier SU, Reynolds HY. 1985. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis 151: 589&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pubmed">3919115</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Falcon MF, Echague CG, Hair PS, Nyalwidhe JO, Cunnion KM. 2011. Protease inhibitors decrease IgG shedding from Staphylococcus aureus, increasing complement activation and phagocytosis efficiency. J Med Microbiol 60: 1415&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">21636671</ArticleId></ArticleIdList></Reference><Reference><Citation>Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, et al. 2009. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A 106: 17864&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758810</ArticleId><ArticleId IdType="pubmed">19815504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan RE, Fernandez J, Brezski RJ, Greenplate AR, Knight DM, et al. 2016. A peptide immunization approach to counteract a Staphylococcus aureus protease defense against host immunity. Immunol Lett 172: 29&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">26905931</ArticleId></ArticleIdList></Reference><Reference><Citation>Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, et al. 2008. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol 181: 3183&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pubmed">18713989</ArticleId></ArticleIdList></Reference><Reference><Citation>Brezski RJ, Jordan RE. 2010. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs 2: 212&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881249</ArticleId><ArticleId IdType="pubmed">20400859</ArticleId></ArticleIdList></Reference><Reference><Citation>Brezski RJ, Oberholtzer A, Strake B, Jordan RE. 2011. The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge. MAbs 3: 558&#x2013;67</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242842</ArticleId><ArticleId IdType="pubmed">22123056</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G, Dekkers G, Rispens T. 2014. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5: 520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202688</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan AR, Winter G. 1988. The binding site for C1q on IgG. Nature 332: 738&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">3258649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinder M, Greenplate AR, Grugan KD, Soring KL, Heeringa KA, et al. 2013. Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem 288: 30843&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829399</ArticleId><ArticleId IdType="pubmed">23986451</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam DH, Lee KB, Kruchowy E, Pham H, Ge X. 2020. Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies. Biochemistry 59: 3802&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7572768</ArticleId><ArticleId IdType="pubmed">32997500</ArticleId></ArticleIdList></Reference><Reference><Citation>Everett MJ, Davies DT. 2021. Pseudomonas aeruginosa elastase (LasB) as a therapeutic target. Drug Discov Today 26: 2108&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">33676022</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiris S, Davies DT, Sprynski N, Castandet J, Beyria L, et al. 2021. Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors. ACS Med Chem Lett 12: 217&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883467</ArticleId><ArticleId IdType="pubmed">33603968</ArticleId></ArticleIdList></Reference><Reference><Citation>Santajit S, Kong-Ngoen T, Chongsa-Nguan M, Boonyuen U, Pumirat P, et al. 2021. Human Single-Chain Antibodies That Neutralize Elastolytic Activity of Pseudomonas aeruginosa LasB. Pathogens 10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8234315</ArticleId><ArticleId IdType="pubmed">34204417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolska K, Szweda P. 2009. Genetic features of clinical Pseudomonas aeruginosa strains. Pol J Microbiol 58: 255&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">19899619</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EJ, Visai L, Kerrigan SW, Speziale P, Foster TJ. 2011. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect Immun 79: 3801&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3165492</ArticleId><ArticleId IdType="pubmed">21708997</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Loghem E, Frangione B, Recht B, Franklin EC. 1982. Staphylococcal protein A and human IgG subclasses and allotypes. Scand J Immunol 15: 275&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">7089488</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe W, Durgannavar TA, Chung SJ. 2016. Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides. Materials (Basel) 9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5456964</ArticleId><ArticleId IdType="pubmed">28774114</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz AR, Boer MAD, Strasser J, Zwarthoff SA, Beurskens FJ, et al. 2021. Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer formation. Proc Natl Acad Sci U S A 118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896290</ArticleId><ArticleId IdType="pubmed">33563762</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg LJ, Humphries JE, Jones SD, Pearce LB, Holgate R, et al. 2019. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv 5: eaax9586</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6920022</ArticleId><ArticleId IdType="pubmed">31897428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz AR, Bentlage AEH, Blonk R, de Haas CJC, Aerts PC, et al. 2022. Toward Understanding How Staphylococcal Protein A Inhibits IgG-Mediated Phagocytosis. J Immunol 209: 1146&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pubmed">36002230</ArticleId></ArticleIdList></Reference><Reference><Citation>Roben PW, Salem AN, Silverman GJ. 1995. VH3 family antibodies bind domain D of staphylococcal protein A. J Immunol 154: 6437&#x2013;45</Citation><ArticleIdList><ArticleId IdType="pubmed">7759880</ArticleId></ArticleIdList></Reference><Reference><Citation>Boero E, Cruz AR, Pansegrau W, Giovani C, Rooijakkers SHM, et al. 2022. Natural Human Immunity Against Staphylococcal Protein A Relies on Effector Functions Triggered by IgG3. Front Immunol 13: 834711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8963248</ArticleId><ArticleId IdType="pubmed">35359919</ArticleId></ArticleIdList></Reference><Reference><Citation>Varshney AK, Kuzmicheva GA, Lin J, Sunley KM, Bowling RA Jr., et al. 2018. A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One 13: e0190537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783355</ArticleId><ArticleId IdType="pubmed">29364906</ArticleId></ArticleIdList></Reference><Reference><Citation>Thammavongsa V, Rauch S, Kim HK, Missiakas DM, Schneewind O. 2015. Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus. Vaccine 33: 523&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4378561</ArticleId><ArticleId IdType="pubmed">25488332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HK, Emolo C, DeDent AC, Falugi F, Missiakas DM, Schneewind O. 2012. Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice. Infect Immun 80: 3460&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457578</ArticleId><ArticleId IdType="pubmed">22825452</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Chen X, Sun Y, Kim HK, Schneewind O, Missiakas D. 2021. A protein A based Staphylococcus aureus vaccine with improved safety. Vaccine 39: 3907&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8259053</ArticleId><ArticleId IdType="pubmed">34088508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar GA, Dang W, Karki S, Vafa O, Peng JS, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103: 4005&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1389705</ArticleId><ArticleId IdType="pubmed">16537476</ArticleId></ArticleIdList></Reference><Reference><Citation>Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, et al. 2012. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 18: 1395&#x2013;403</Citation><ArticleIdList><ArticleId IdType="pubmed">22223529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, et al. 2021. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 7: 573&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7823434</ArticleId><ArticleId IdType="pubmed">33480963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jendeberg L, Nilsson P, Larsson A, Denker P, Uhlen M, et al. 1997. Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A. J Immunol Methods 201: 25&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">9032407</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Schneewind O, Missiakas D. 2022. Engineered human antibodies for the opsonization and killing of Staphylococcus aureus. Proc Natl Acad Sci U S A 119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8795526</ArticleId><ArticleId IdType="pubmed">35058363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu TH, Patz EF Jr., Ackerman ME. 2021. Coming together at the hinges: Therapeutic prospects of IgG3. MAbs 13: 1882028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7899677</ArticleId><ArticleId IdType="pubmed">33602056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprague ER, Wang C, Baker D, Bjorkman PJ. 2006. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol 4: e148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450327</ArticleId><ArticleId IdType="pubmed">16646632</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprague ER, Reinhard H, Cheung EJ, Farley AH, Trujillo RD, et al. 2008. The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol 82: 3490&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268481</ArticleId><ArticleId IdType="pubmed">18216124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndjamen B, Joshi DS, Fraser SE, Bjorkman PJ. 2016. Characterization of Antibody Bipolar Bridging Mediated by the Human Cytomegalovirus Fc Receptor gp68. J Virol 90: 3262&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810659</ArticleId><ArticleId IdType="pubmed">26739053</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks JA, Goodwin ML, Permar SR. 2019. The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity. Front Immunol 10: 2110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742691</ArticleId><ArticleId IdType="pubmed">31555298</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank I, Friedman HM. 1989. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol 63: 4479&#x2013;88</Citation><ArticleIdList><ArticleId IdType="pmc">PMC251078</ArticleId><ArticleId IdType="pubmed">2552134</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley K, Anderson J, Yang F, Szustakowski J, Oakeley EJ, et al. 2011. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10: 197&#x2013;209</Citation><ArticleIdList><ArticleId IdType="pubmed">21925108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb P, Hoffmann K, Sievert A, Reinhard H, Merce-Maldonado E, et al. 2021. Human cytomegalovirus antagonizes activation of Fcgamma receptors by distinct and synergizing modes of IgG manipulation. Elife 10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8041466</ArticleId><ArticleId IdType="pubmed">33724188</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubinski JM, Lazear HM, Awasthi S, Wang F, Friedman HM. 2011. The Herpes Simplex Virus 1 IgG Fc Receptor Blocks Antibody-Mediated Complement Activation and Antibody-Dependent Cellular Cytotoxicity In Vivo. Journal of Virology 85: 3239&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067879</ArticleId><ArticleId IdType="pubmed">21228231</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrales-Aguilar E, Trilling M, Hunold K, Fiedler M, Le VT, et al. 2014. Human cytomegalovirus Fcgamma binding proteins gp34 and gp68 antagonize Fcgamma receptors I, II and III. PLoS Pathog 10: e1004131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022731</ArticleId><ArticleId IdType="pubmed">24830376</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlahava V-M, Murrell I, Zhuang L, Aicheler RJ, Lim E, et al. 2021. Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. The Journal of Clinical Investigation 131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880312</ArticleId><ArticleId IdType="pubmed">33586678</ArticleId></ArticleIdList></Reference><Reference><Citation>Qerqez AN HK, Lee AG, Mishra AK, Delidakis G, Chowdhury A, Nguyen AW, Georgiou G, McLellan JS, Hengel H, and Maynard JA. 2023. Uncoupling antibody binding to host and viral Fc receptors restores antibodymediated NK cell activation against HCMV-infected cells. submitted</Citation></Reference><Reference><Citation>Joller N, Weber SS, Muller AJ, Sporri R, Selchow P, et al. 2010. Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proc Natl Acad Sci U S A 107: 20441&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996673</ArticleId><ArticleId IdType="pubmed">21048081</ArticleId></ArticleIdList></Reference><Reference><Citation>Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, et al. 2014. Complement is activated by IgG hexamers assembled at the cell surface. Science 343: 1260&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250092</ArticleId><ArticleId IdType="pubmed">24626930</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen MD, Kuipers-De Wilt L, van Egmond ML, Reinders-Blankert P, van den Bremer ETJ, et al. 2022. Biophysical Characterization and Stability of Modified IgG1 Antibodies with Different Hexamerization Propensities. J Pharm Sci 111: 1587&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pubmed">35235843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, et al. 2019. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol 17: e3000323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602280</ArticleId><ArticleId IdType="pubmed">31216278</ArticleId></ArticleIdList></Reference><Reference><Citation>Meri S, Jordens M, Jarva H. 2008. Microbial complement inhibitors as vaccines. Vaccine 26 Suppl 8: I113&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">19388175</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79: 3751&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3165461</ArticleId><ArticleId IdType="pubmed">21708990</ArticleId></ArticleIdList></Reference><Reference><Citation>Biolchi A, Tomei S, Santini L, La Gaetana R, Mori E, et al. 2021. Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents. Pediatr Infect Dis J 40: e66&#x2013;e71</Citation><ArticleIdList><ArticleId IdType="pubmed">33060520</ArticleId></ArticleIdList></Reference><Reference><Citation>Granoff DM, Giuntini S, Gowans FA, Lujan E, Sharkey K, Beernink PT. 2016. Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding. JCI Insight 1: e88907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5033880</ArticleId><ArticleId IdType="pubmed">27668287</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiriard A, Raze D, Locht C. 2018. Diversion of complement-mediated killing by Bordetella. Microbes Infect 20: 512&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pubmed">29454132</ArticleId></ArticleIdList></Reference><Reference><Citation>Badarau A, Trstenjak N, Nagy E. 2017. Structure and Function of the Two-Component Cytotoxins of Staphylococcus aureus - Learnings for Designing Novel Therapeutics. Adv Exp Med Biol 966: 15&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">28455832</ArticleId></ArticleIdList></Reference><Reference><Citation>Francois B, Jafri HS, Chastre J, Sanchez-Garcia M, Eggimann P, et al. 2021. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infect Dis 21: 1313&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pubmed">33894131</ArticleId></ArticleIdList></Reference><Reference><Citation>Francois B, Mercier E, Gonzalez C, Asehnoune K, Nseir S, et al. 2018. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med 44: 1787&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pubmed">30343314</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, et al. 2015. Five birds, one stone: neutralization of alpha-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 7: 243&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5045134</ArticleId><ArticleId IdType="pubmed">25523282</ArticleId></ArticleIdList></Reference><Reference><Citation>Szijarto V, Guachalla LM, Hartl K, Varga C, Badarau A, et al. 2017. Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258. Virulence 8: 1203&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5711440</ArticleId><ArticleId IdType="pubmed">28103139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouha H, Weber S, Janesch P, Maierhofer B, Gross K, et al. 2018. Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies. Virulence 9: 231&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5955178</ArticleId><ArticleId IdType="pubmed">29099326</ArticleId></ArticleIdList></Reference><Reference><Citation>Magyarics Z, Leslie F, Bartko J, Rouha H, Luperchio S, et al. 2019. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers. Antimicrob Agents Chemother 63</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6658777</ArticleId><ArticleId IdType="pubmed">31138568</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein RL. 2022. Kinetic Studies of the Activation of Bordetella pertussis Adenylate Cyclase by Calmodulin. Biochemistry</Citation><ArticleIdList><ArticleId IdType="pubmed">35263092</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray MC, Hewlett EL. 2011. Cell cycle arrest induced by the bacterial adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis. Cell Microbiol 13: 123&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137770</ArticleId><ArticleId IdType="pubmed">20946259</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedele G, Schiavoni I, Adkins I, Klimova N, Sebo P. 2017. Invasion of Dendritic Cells, Macrophages and Neutrophils by the Bordetella Adenylate Cyclase Toxin: A Subversive Move to Fool Host Immunity. Toxins (Basel) 9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666340</ArticleId><ArticleId IdType="pubmed">28934122</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsmith JA, DiVenere AM, Maynard JA, McLellan JS. 2021. Structural basis for antibody binding to adenylate cyclase toxin reveals RTX linkers as neutralization-sensitive epitopes. PLoS Pathog 17: e1009920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486122</ArticleId><ArticleId IdType="pubmed">34547035</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsmith J, DiVenere A, Maynard J, McLellan J. 2022. Structural Basis for Non-canonical Integrin Engagement by Bordetella Adenylate Cyclase Toxin. Cell Reports, in press</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9416875</ArticleId><ArticleId IdType="pubmed">35977491</ArticleId></ArticleIdList></Reference><Reference><Citation>DiVenere AM, Amengor D, Silva RP, Goldsmith JA, McLellan JS, Maynard JA. 2022. Blockade of the Adenylate Cyclase Toxin Synergizes with Opsonizing Antibodies to Protect Mice against Bordetella pertussis. mBio 13: e0152722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426472</ArticleId><ArticleId IdType="pubmed">35920558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkaczyk C, Kasturirangan S, Minola A, Jones-Nelson O, Gunter V, et al. 2017. Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach. Antimicrob Agents Chemother 61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5527613</ArticleId><ArticleId IdType="pubmed">28584141</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites GE, Gant V. 2011. Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? Nat Rev Microbiol 9: 215&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">21297670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rungelrath V, Porter AR, Malachowa N, Freedman BA, Leung JM, et al. 2021. Further Insight into the Mechanism of Human PMN Lysis following Phagocytosis of Staphylococcus aureus. Microbiol Spectr 9: e0088821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8549732</ArticleId><ArticleId IdType="pubmed">34704790</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMont AL, Yoong P, Surewaard BG, Benson MA, Nijland R, et al. 2013. Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophils. Infect Immun 81: 1830&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648020</ArticleId><ArticleId IdType="pubmed">23509138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, et al. 2015. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 527: 323&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">26536114</ArticleId></ArticleIdList></Reference><Reference><Citation>Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, et al. 2016. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem 8: 1112&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pubmed">27874860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Lehar S, Gutierrez J, Rosenberger CM, Ljumanovic N, et al. 2016. Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs 8: 1612&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5098440</ArticleId><ArticleId IdType="pubmed">27653831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajihara KK, Pantua H, Hernandez-Barry H, Hazen M, Deshmukh K, et al. 2021. Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate. mBio 12: e0020221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262897</ArticleId><ArticleId IdType="pubmed">34061593</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor A, Jenner D, Rowland C, Laws T, Norville I, Prior J. 2021. Monoclonal Antibodies Opsonize Burkholderia spp. and Reduce Intracellular Actin Tail Formation in a Macrophage Infection Assay. J Bacteriol 203: e0024421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8508110</ArticleId><ArticleId IdType="pubmed">34460311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chastre J, Francois B, Bourgeois M, Komnos A, Ferrer R, et al. 2022. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care 26: 355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9666938</ArticleId><ArticleId IdType="pubmed">36380312</ArticleId></ArticleIdList></Reference><Reference><Citation>Heimer SR, Evans DJ, Stern ME, Barbieri JT, Yahr T, Fleiszig SM. 2013. Pseudomonas aeruginosa utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells. PLoS One 8: e73111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776860</ArticleId><ArticleId IdType="pubmed">24058462</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanabalasuriar A, Surewaard BG, Willson ME, Neupane AS, Stover CK, et al. 2017. Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature. J Clin Invest 127: 2249&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451222</ArticleId><ArticleId IdType="pubmed">28463232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, et al. 2016. A &#x201c;Trojan horse&#x201d; bispecific-antibody strategy for broad protection against ebolaviruses. Science 354: 350&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5647781</ArticleId><ArticleId IdType="pubmed">27608667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Ye L, Tesar DB, Song H, Zhao D, et al. 2011. Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci U S A 108: 18406&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215070</ArticleId><ArticleId IdType="pubmed">22042859</ArticleId></ArticleIdList></Reference><Reference><Citation>Caddy SL, Vaysburd M, Wing M, Foss S, Andersen JT, et al. 2020. Intracellular neutralisation of rotavirus by VP6-specific IgG. PLoS Pathog 16: e1008732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7428215</ArticleId><ArticleId IdType="pubmed">32750093</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBowitz JH, Grubb JH, Maga JA, Schmiel DH, Vogler C, Sly WS. 2004. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A 101: 3083&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365748</ArticleId><ArticleId IdType="pubmed">14976248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirchnianski AS, Wec AZ, Nyakatura EK, Herbert AS, Slough MM, et al. 2021. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity. Front Immunol 12: 729851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8551868</ArticleId><ArticleId IdType="pubmed">34721393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>